Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 1/20 | 0.47 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.47 |
| ▸ | CTSS | P25774 | 5/20 | 0.43 |
| ▸ | CTSL | P07711 | 4/20 | 0.43 |
| ▸ | CTSB | P07858 | 3/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | CTSK | P43235 | 4/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.40 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | APEX1 | P27695 | 1/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL560681 | 1.00 | DDB1 (0.47) | DDB1CRBNCTSSCTSLCTSB | |
| SCHEMBL2297578 | 0.89 | DDB1 (0.49) | DDB1CRBNCTSSCTSLCTSB | |
| SCHEMBL12355229 | 0.80 | DDB1 (0.47) | DDB1CRBNCTSSCTSLCTSB | |
| SCHEMBL560572 | 0.77 | POLB (0.38) | SMN1; SMN2GAAKDM4EALDH1A1MAPT | |
| SCHEMBL560573 | 0.77 | POLB (0.38) | SMN1; SMN2GAAKDM4EALDH1A1MAPT | |
| SCHEMBL2913795 | 0.76 | CTSS (0.55) | CTSSCTSLCTSBNPC1RAB9A | |
| SCHEMBL1324347 | 0.76 | DDB1 (0.42) | DDB1CRBNCTSSCTSLCTSB | |
| SCHEMBL1974652 | 0.75 | CTSB (0.51) | CTSSCTSLCTSBNPC1RAB9A | |
| SCHEMBL12424729 | 0.75 | DDB1 (0.47) | DDB1CRBNCTSSCTSLCTSB | |
| SCHEMBL10332172 | 0.74 | CTSS (0.59) | CTSSCTSLCTSBNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9434737-B2 | Process for producing optically active succinimide derivatives and intermediates thereof | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2016-09-06 | — | — | US | disclosed |
| US-8900830-B2 | Process for producing optically active succinimide derivatives | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2014-12-02 | — | — | US | disclosed |
| US-20140099681-A1 | PROCESS FOR PRODUCING OPTICALLY ACTIVE SUCCINIMIDE DERIVATIVES AND INTERMEDIATES THEREOF | KYOWA HAKKO BIO CO., LTD. (JP) | 2014-04-10 | — | — | US | disclosed |
| US-8633001-B2 | Process for producing optically active succinimide derivatives and intermediates thereof | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2014-01-21 | — | — | US | disclosed |
| US-20130196388-A1 | PROCESS FOR PRODUCING OPTICALLY ACTIVE SUCCINIMIDE DERIVATIVES | KYOWA HAKKO BIO CO., LTD. (JP) | 2013-08-01 | — | — | US | disclosed |
| EP-2058300-B1 | SUCCINIC ACID DIESTER DERIVATIVE, PROCESS FOR PRODUCTION THEREOF, AND USE OF THE DERIVATIVE IN THE PRODUCTION OF PHARMACEUTICAL PREPARATION | DAINIPPON SUMITOMO PHARMA CO (JP) | 2013-01-09 | — | — | EP | disclosed |
| US-20120034660-A1 | PROCESS FOR PRODUCING OPTICALLY ACTIVE SUCCINIMIDE DERIVATIVES AND INTERMEDIATES THEREOF | KYOWA HAKKO BIO CO., LTD. (JP) | 2012-02-09 | — | — | US | disclosed |
| US-8106230-B2 | Succinic acid diester derivative, process for production thereof, and use of the derivative in the production of pharmaceutical preparation | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2012-01-31 | — | — | US | disclosed |
| EP-2395097-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE SUCCINIMIDE DERIVATIVE AND INTERMEDIATE THEREOF | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2011-12-14 | — | — | EP | disclosed |
| US-8030486-B2 | Succinic acid diester derivative, process for production thereof, and use of the derivative in the production of pharmaceutical preparation | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2011-10-04 | — | — | US | disclosed |
| US-7994342-B2 | Method for producing optically active succinimide compound | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2011-08-09 | — | — | US | disclosed |
| US-7994342-B2 | Method for producing optically active succinimide compound | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2011-08-09 | — | — | US | disclosed |
| US-20110046373-A1 | SUCCINIC ACID DIESTER DERIVATIVE, PROCESS FOR PRODUCTION THEREOF, AND USE OF THE DERIVATIVE IN THE PRODUCTION OF PHARMACEUTICAL PREPARATION | INAGAKI TAKASHI | 2011-02-24 | — | — | US | disclosed |
| US-20100076203-A1 | Succinic acid diester derivative, process for production thereof, and use of the derivative in the production of pharmaceutical preparation | DAINIPPON SUMITOMO PHARMA CO., LTD. | 2010-03-25 | — | — | US | disclosed |
| US-20100003729-A1 | Method for producing optically active succinimide compound | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2010-01-07 | — | — | US | disclosed |
| US-20100003729-A1 | Method for producing optically active succinimide compound | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2010-01-07 | — | — | US | disclosed |
| EP-2071033-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE SUCCINIMIDE COMPOUND | Nissan Chemical Industries, Ltd. (JP) | 2009-06-17 | — | — | EP | disclosed |
| EP-2058300-A1 | SUCCINIC ACID DIESTER DERIVATIVE, PROCESS FOR PRODUCTION THEREOF, AND USE OF THE DERIVATIVE IN THE PRODUCTION OF PHARMACEUTICAL PREPARATION | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2009-05-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110046373-A1 | SUCCINIC ACID DIESTER DERIVATIVE, PROCESS FOR PRODUCTION THEREOF, AND USE OF THE DERIVATIVE IN THE PRODUCTION OF PHARMACEUTICAL PREPARATION | SUCNR1, DLST, SHMT2 | DDB1 3582/4885CRBN 4612/4885CTSS 2059/4885 |
| US-20140099681-A1 | PROCESS FOR PRODUCING OPTICALLY ACTIVE SUCCINIMIDE DERIVATIVES AND INTERMEDIATES THEREOF | SDHA, STS, DHPS | DDB1 3625/4885CRBN 2003/4885CTSS 2527/4885 |
| US-20120034660-A1 | PROCESS FOR PRODUCING OPTICALLY ACTIVE SUCCINIMIDE DERIVATIVES AND INTERMEDIATES THEREOF | SDHA, STS, ALDH18A1 | DDB1 3648/4885CRBN 1752/4885CTSS 2557/4885 |
| US-20100076203-A1 | Succinic acid diester derivative, process for production thereof, and use of the derivative in the production of pharmaceutical preparation | SUCNR1, DLST, SHMT2 | DDB1 3582/4885CRBN 4612/4885CTSS 2059/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.